DNAH17-AS1 promotes pancreatic carcinoma by increasing PPME1 expression via inhibition of miR-432-5p

BACKGROUND The incidence and mortality rates of pancreatic carcinoma(PC) are rapidly increasing worldwide. Long noncoding RNAs(lnc RNAs) play critical roles during PC initiation and progression. Since the lnc RNA DNAH17-AS1 is highly expressed in PC, the regulation of DNAH17-AS1 in PC was investigated in this study.AIM To investigate the expression and molecular action of lnc RNA DNAH17-AS1 in PC cells.METHODS The PC expression data for the lnc RNA DNAH17-AS1 was downloaded from The Cancer Genome Atlas database and used to examine its profile. Western blot and reverse transcription-quantitative PCR were employed to assess protein and m RNA expression. A subcellular fractionation assay was used to determine the location of DNAH17-AS1 in cells. In addition, the regulatory effects of DNAH17-AS1 on mi R-432-5 p, PPME1, and tumor activity were investigated using luciferase reporter assay, MTT viability analysis, flow cytometry, and transwell migration analysis.RESULTS DNAH17-AS1 was upregulated in PC cells and was associated with aggressive tumor behavior and poor prognosis for patients. Silencing DNAH17-AS1 promoted the apoptosis and reduced the viability, invasion, and migration of PC cells. In addition, DNAH17-AS1 served as a PC oncogene by downregulating mi R-432-5 p which normally directly targeted PPME1 to downregulate its expression.CONLUSION DNAH17-AS1 functions in PC as a tumor promoter by regulating the mi R-432-5 p/PPME1 axis. This finding may provide new insights for PC prognosis and therapy.